Stockscreener 앱 받기
3.57
2.19%
-0.08
시간 외 거래:
3.57
전일 마감가:
$3.65
열려 있는:
$3.62
하루 거래량:
382.76K
Relative Volume:
0.33
시가총액:
$442.24M
수익:
$69.56M
순이익/손실:
$-240.05M
주가수익비율:
-1.2102
EPS:
-2.95
순현금흐름:
$-121.90M
1주 성능:
+1.13%
1개월 성능:
+10.87%
6개월 성능:
+24.39%
1년 성능:
+85.94%
1일 변동 폭
$3.52
$3.66
1주일 범위
$3.38
$3.7499
52주 변동 폭
$1.05
$4.80
Adc Therapeutics Sa Stock (ADCT) Company Profile
명칭
Adc Therapeutics Sa
전화
41 21 653 02 00
주소
BIOPOLE, EPALINGES
ADCT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ADCT
Adc Therapeutics Sa
|
3.57 | 452.15M | 69.56M | -240.05M | -121.90M | -2.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Adc Therapeutics Sa Stock (ADCT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-11-08 | 개시 | Stephens | Overweight |
| 2024-05-30 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-03-28 | 개시 | Guggenheim | Buy |
| 2023-08-10 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2023-04-24 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-12-06 | 개시 | CapitalOne | Overweight |
| 2022-11-09 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-09-21 | 개시 | JP Morgan | Overweight |
| 2022-09-09 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-11-09 | 개시 | Wolfe Research | Outperform |
| 2021-08-17 | 재개 | Jefferies | Buy |
| 2021-08-09 | 개시 | RBC Capital Mkts | Outperform |
| 2021-06-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-12-03 | 개시 | Stifel | Hold |
| 2020-10-29 | 개시 | H.C. Wainwright | Buy |
| 2020-06-09 | 개시 | BofA/Merrill | Buy |
| 2020-06-09 | 개시 | Cowen | Outperform |
모두보기
Adc Therapeutics Sa 주식(ADCT)의 최신 뉴스
ADC Therapeutics Announces Preliminary 2025 Financial Results and Outlook - TipRanks
Can ADC Therapeutics SA stock rebound after recent weakness2025 Winners & Losers & Free Reliable Trade Execution Plans - ulpravda.ru
ADC Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Revenue and Cash Estimates and Recent Corporate Updates - PR Newswire
ADC Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference - Nasdaq
ADC Therapeutics SA Common Shares (NY: ADCT - markets.financialcontent.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC ... - Bluefield Daily Telegraph
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SAADCT - FinancialContent
Will ADC Therapeutics SA stock outperform international peers2026 world cup usa national team round of 32 top scorers high defensive line tactical prediction guide - ulpravda.ru
ADCT stock touches 52-week low at $1.42 amid market challenges - MSN
ADC Therapeutics Announces New Employee Inducement Grant - 富途牛牛
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Graphic Packaging Holding Company - GlobeNewswire Inc.
ADC Therapeutics (ADCT) Upgraded to Buy: Here's Why - Yahoo Finance
Is ADC Therapeutics SA a good long term investmentOptions Trading Strategies & Free Take Advantage Of Momentum - earlytimes.in
Corient Private Wealth LLC Makes New Investment in ADC Therapeutics SA $ADCT - MarketBeat
Risk Report: Will ADC Therapeutics SA stock beat EPS estimatesQuarterly Profit Report & Fast Gaining Stock Reports - Улправда
How geopolitical tensions affect ADC Therapeutics SA stockJuly 2025 Analyst Calls & Fast Entry and Exit Trade Plans - Улправда
Can ADC Therapeutics SA Common Shares stock sustain margin levelsTrade Risk Assessment & Real-Time Stock Entry Alerts - Улправда
Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines - marketscreener.com
Is ADC Therapeutics SA stock a contrarian buyJuly 2025 Macro Moves & Fast Gaining Stock Strategy Reports - Улправда
ADC Therapeutics SA (NYSE:ADCT) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Will ADC Therapeutics SA stock beat EPS estimatesMarket Activity Report & Safe Entry Zone Identification - Улправда
Is ADC Therapeutics SA Common Shares stock testing key supportJuly 2025 WrapUp & Weekly Stock Breakout Alerts - Улправда
Wall Street Recap: Is ADC Therapeutics SA Common Shares stock undervalued historically2025 EndofYear Setup & Weekly High Return Forecasts - Улправда
How buybacks impact ADC Therapeutics SA stock value2025 Investor Takeaways & Entry and Exit Point Strategies - Улправда
Is ADC Therapeutics SA Common Shares stock undervalued historically2025 Big Picture & Weekly Momentum Stock Picks - Улправда
RBC Capital Bullish on ADC Therapeutics S.A. (ADCT) on Lymphoma Treatment Development - Yahoo Finance
Is ADC Therapeutics (ADCT) Stock Outpacing Its Medical Peers This Year? - sharewise.com
ADC Therapeutics (NYSE:ADCT) Sees Large Volume IncreaseStill a Buy? - MarketBeat
ADC Therapeutics SA (ADCT) is a Great Momentum Stock: Should You Buy? - sharewise.com
ADC Therapeutics SA (NYSE:ADCT) Q1 2025 Earnings Call Transcript - MSN
ADC Therapeutics SA Stock Analysis and ForecastHigh Beta Stocks & Predict Price Movements With AI Precision - earlytimes.in
CEO Mallik Surrenders 233,146 Of ADC Therapeutics SA [ADCT] - TradingView — Track All Markets
Officer Graham Surrenders 49,508 Of ADC Therapeutics SA [ADCT] - TradingView — Track All Markets
ADC Therapeutics (NYSE: ADCT) CEO reports 233,146-share tax withholding - Stock Titan
ADC Therapeutics (ADCT) CMO has 41,068 shares withheld for RSU taxes - Stock Titan
ADC Therapeutics (ADCT) CAO reports 7,140 shares withheld for RSU tax and holds 70,757 - Stock Titan
ADC Therapeutics (ADCT) CLO Peter Graham reports tax share withholding - Stock Titan
ADC Therapeutics (ADCT) CFO reports 53,236-share tax withholding from RSU vesting - Stock Titan
ADC Therapeutics (ADCT) files S-3/A Amendment No. 1 to add new auditor consent - Stock Titan
Adc Therapeutics SA (ADCT) expanding its growth trajectory ahead - setenews.com
ADC Therapeutics reports promising LOTIS-7 trial results - MSN
ADC Therapeutics Reports Promising LOTIS-7 Trial Results - TipRanks
ADC Therapeutics Updates LOTIS-7 Trial Data - TradingView — Track All Markets
[8-K] ADC Therapeutics SA Reports Material Event | ADCT SEC FilingForm 8-K - Stock Titan
Is ADC Therapeutics SA Common Shares stock attractive post correction2025 Institutional Moves & Growth Focused Investment Plans - Newser
Is ADC Therapeutics SA stock oversold or undervalued2025 Market WrapUp & Scalable Portfolio Growth Ideas - Newser
What momentum indicators show for ADC Therapeutics SA stockShare Buyback & Accurate Entry and Exit Point Alerts - Newser
Adc Therapeutics Sa (ADCT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.80%
4.56%
자본화:
|
볼륨(24시간):